Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Basal Cell 11Ovarian Neoplasms 2Neoplasms 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Solid Cancers 1Neoplasms, Unknown Primary 1Neoplasms, Basal Cell 1Myelodysplastic Syndromes 1Leukemia, Myeloid 1Biliary Tract Neoplasms 1

Interventions

PR-104 3apomine 2N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide 2tesetaxel 1ixabepilone 1intoplicine 1fluoromisonidazole 1eribulin 1bempegaldesleukin 1HhAntag691 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1Docetaxel 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Unspecified Adult Solid Tumor, Protocol Specific × HhAntag691 × Clear all
NCT00607724 2015-10-08

GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Completed
68 enrolled 22 charts
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡